Arginase 1 monoclonal antibody

L-arginine plays a critical role in regulating the immune system (1-3) . In inflammation, cancer and certain other pathological conditions, myeloid cell differentiation is inhibited leading to a heterogeneous population of immature myeloid cells, known as myeloid-derived suppressor cells (MDSCs) . MDSCs are recruited to sites of cancer-associated inflammation and express high levels of arginase-1 . Arginase-1 catalyzes the final step of the urea cycle converting L-arginine to L-ornithine and urea . Thus MDSCs increase the catabolism of L-arginine resulting in L-arginine depletion in the inflammatory microenvironment of cancer (4,6) . The reduced availability of L-arginine suppresses T-cell proliferation and function and thus contributes to tumor progression (4,6) . Arginase-1 is of great interest to researchers looking for a therapeutic target to inhibit the function of MDSCs in the context of cancer immunotherapy . In addition, research studies have demonstrated that Arginase-1 distinguishes primary hepatocellular carcinoma (HCC) from metastatic tumors in the liver, indicating its value as a potential biomarker in the diagnosis of HCC

The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .